Results Press Release for September 30, 2016
Pfizer Ltd has informed BSE about : 1. Result Press Release for the period ended September 30, 201604-11-2016
04-11-2016
Announces Q2 results (Standalone) & Limited Review Report (Standalone) for the Quarter ended September 30, 2016
Pfizer Ltd has announced the following Unaudited Standalone results for the quarter ended September 30, 2016:The Company has posted a net profit of Rs. 1263.30 million for the quarter ended September 30, 2016 as compared to Rs. 828.40 million for the quarter ended September 30, 2015. Total Income has increased from Rs. 5472.00 million for the quarter ended September 30, 2015 to Rs. 5819.60 million for the quarter ended September 30, 2016.04-11-2016
Pfizer profit just misses estimates; company scraps cholesterol drug
The drugmaker earned 61 cents per share in the third quarter, excluding special items, missing the average analyst estimate by 1 cent01-11-2016
Q2 results on Nov 04, 2016
Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on November 4, 2016, inter alia, to consider and take on record the unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2016 (Q2).Further, the Trading Window for trading in the Equity shares of the Company will be closed from October 26, 2016 to November 6, 2016, both days inclusive.25-10-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Pfizer Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.16-10-2016
Shareholding for the Period Ended September 30, 2016
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here15-10-2016
Novartis challenges Pfizer with strong breast cancer drug data
Novartis' ribociclib to take on Pfizer blockbuster Ibrance08-10-2016
AstraZeneca pharma lays-off 50 sales employees, faces protest
Under restructuring company sold-off its antibiotic business to Pfizer in August01-10-2016
Pfizer concludes Rs 110cr deal with Piramal Enterprises
The acquisition includes brands Ferradol, Neko, Sloan's and Waterbury's compound.26-09-2016
Completion of Transaction of the Sale of Four Products to Piramal Enterprises Limited
Pfizer Ltd vide its letter dated September 26, 2016 has informed BSE regarding "Completion of Transaction of the Sale of Four Products to Piramal Enterprises Limited".26-09-2016